Foxo Technologies announces closing of Vector Biosource acquisition

FOXO Technologies (FOXO) announces the closing of the acquisition of Vector Biosource. Vector is an information, data and biospecimen sourcing provider serving the biotechnology, clinical research and pharmaceutical research industries. Vector generated second quarter 2025 net revenues of approximately $225,000 and is expected to grow significantly post-acquisition. The purchase price consists of: $500,000 in cash, 60,000 shares of the Company’s Series E Cumulative Redeemable Secured Preferred Stock, warrants to purchase $2 million of the Company’s common stock at a 10% premium to the common stock’s closing price one day prior to closing, and up to an additional 80,000 shares of Series E Preferred Stock subject to achieving certain revenue and cash collection milestones in a future 12 to 24 month period. In addition, FOXO has agreed to fund up to $1.2 million of Vector’s growth initiatives.